Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs

Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.

Asia Deal Watch
• Source: Alamy

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker.

Marking their third agreement in the last seven months, Merck & Co., Inc. and Sichuan Kelun Pharmaceutical Co Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal Watch

More from Deals